Ceftriaxone: Difference between revisions
No edit summary |
(→General: edited dosage forms, strengths) |
||
(11 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: 3rd generation [[ | *Type: {{#set:cephalosporin generation =3rd}} 3rd generation [[Antibiotic class::Cephalosporin]] | ||
*Dosage Forms: | *Dosage Forms: injectable solution, powder for injection | ||
*Dosage Strengths: injectable solution: 1g/50mL, 2g/50mL; powder for injection: 250mg, 500mg, 1g, 2g, 10g, 100g | |||
*Routes of Administration: IV, IM | |||
*Common Trade Names: Rocephin | *Common Trade Names: Rocephin | ||
Line 49: | Line 51: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===General (<7 Days Old)=== | ===General (<7 Days Old)=== | ||
* | *50mg/kg IM/IV q24h | ||
*First Dose: | *First Dose: 50mg/kg IM/IV x 1 | ||
===General (7 Days - 1 Month)=== | ===General (7 Days - 1 Month)=== | ||
*<2000g | *<2000g | ||
** | **50mg/kg IM/IV q24h | ||
**First Dose: | **First Dose: 50mg/kg IM/IV x 1 | ||
*>2000g | *>2000g | ||
**50- | **50-75mg/kg IM/IV q24h | ||
**First Dose: 50- | **First Dose: 50-75mg/kg IM/IV x 1 | ||
===General (>1 Month - Adult)=== | ===General (>1 Month - Adult)=== | ||
*50- | *50-100mg/kg IM/IV divided q12-24h | ||
*First Dose: 50- | *First Dose: 50-100mg/kg IM/IV x 1 | ||
*Max: 4g/24h | *Max: 4g/24h | ||
===Acute [[Otitis Media]] (2 Months - 12 Years)=== | ===Acute [[Otitis Media]] (2 Months - 12 Years)=== | ||
* | *50mg/kg IM/IV x 1 | ||
*Give | *Give 50mg/kg IM/IV q24h x 3 days for recurrent infection | ||
*Max 1g/dose | *Max 1g/dose | ||
===Bacterial [[Meningitis]]=== | ===Bacterial [[Meningitis]]=== | ||
*80- | *80-100mg/kg IV divided q12-24h x 7-21 days | ||
*First Dose: 100mg/kg IV x 1 | *First Dose: 100mg/kg IV x 1 | ||
*Max: 4g/24h | *Max: 4g/24h | ||
===[[Pneumonia]], Community-Acquired (>3 Months)=== | ===[[Pneumonia]], Community-Acquired (>3 Months)=== | ||
*50- | *50-100mg/kg/day IM/IV divided q12-24h x 10 days | ||
*First Dose: | *First Dose: | ||
*Max: 2g/day | *Max: 2g/day | ||
Line 82: | Line 84: | ||
==Special Populations== | ==Special Populations== | ||
*Pregnancy: B | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | ||
*Lactation: Probably safe | *Lactation: Probably safe | ||
*Renal Dosing | *Renal Dosing | ||
Line 91: | Line 93: | ||
**Pediatric | **Pediatric | ||
***CrCl <10: give q24h | ***CrCl <10: give q24h | ||
***Hemodialysis: | ***Hemodialysis: 50mg/kg q24, no supplement | ||
***Peritoneal Dialysis: | ***Peritoneal Dialysis: 50mg/kg q24, no supplement | ||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult | **Adult | ||
Line 100: | Line 102: | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug (see also [[Cephalosporin Cross-reactivity]] | *Allergy to class/drug (see also [[Cephalosporin Cross-reactivity]]) | ||
*Patients <1 month old | *Patients <1 month old | ||
**Hyperbillirubinemia | **Hyperbillirubinemia | ||
**IV calcium containing product | **IV calcium containing product | ||
**If a 3rd generation cephalosporin is required, consider using Cefotaxime instead | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
Line 143: | Line 146: | ||
*Excretion: Primarily urine | *Excretion: Primarily urine | ||
*Mechanism of Action: bactericidal; inhibits cell wall synthesis | *Mechanism of Action: bactericidal; inhibits cell wall synthesis | ||
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | |||
{| class="wikitable" | |||
| align="center" style="background:#f0f0f0;"|'''Group''' | |||
| align="center" style="background:#f0f0f0;"|'''Organism''' | |||
| align="center" style="background:#f0f0f0;"|'''Sensitivity''' | |||
|- | |||
| Gram Positive||[[Strep. Group A, B, C, G]]||'''S''' | |||
|- | |||
| ||[[Strep. Pneumoniae]]||'''S''' | |||
|- | |||
| ||[[Viridans strep]]||'''S''' | |||
|- | |||
| ||Strep. anginosus gp||X1 | |||
|- | |||
| ||[[Enterococcus faecalis]]||R | |||
|- | |||
| ||[[Enterococcus faecium]]||X1 | |||
|- | |||
| ||[[MSSA]]||'''S''' | |||
|- | |||
| ||[[MRSA]]||R | |||
|- | |||
| ||[[CA-MRSA]]||R | |||
|- | |||
| ||[[Staph. Epidermidis]]||I | |||
|- | |||
| ||[[C. jeikeium]]||R | |||
|- | |||
| ||[[L. monocytogenes]]||R | |||
|- | |||
| Gram Negatives||[[N. gonorrhoeae]]||I | |||
|- | |||
| ||[[N. meningitidis]]||'''S''' | |||
|- | |||
| ||[[Moraxella catarrhalis]]||'''S''' | |||
|- | |||
| ||[[H. influenzae]]||'''S''' | |||
|- | |||
| ||[[E. coli]]||'''S''' | |||
|- | |||
| ||[[Klebsiella]] sp||'''S''' | |||
|- | |||
| ||E. coli/Klebsiella ESBL+||R | |||
|- | |||
| ||E coli/Klebsiella KPC+||R | |||
|- | |||
| ||[[Enterobacter]] sp, AmpC neg||'''S''' | |||
|- | |||
| ||[[Enterobacter]] sp, AmpC pos||R | |||
|- | |||
| ||[[Serratia]] sp||'''S''' | |||
|- | |||
| ||Serratia marcescens||X1 | |||
|- | |||
| ||[[Salmonella]] sp||'''S''' | |||
|- | |||
| ||[[Shigella]] sp||'''S''' | |||
|- | |||
| ||[[Proteus mirabilis]]||'''S''' | |||
|- | |||
| ||[[Proteus vulgaris]]||'''S''' | |||
|- | |||
| ||[[Providencia sp.]]||'''S''' | |||
|- | |||
| ||[[Morganella sp.]]||'''S''' | |||
|- | |||
| ||[[Citrobacter freundii]]||'''S''' | |||
|- | |||
| ||[[Citrobacter diversus]]||'''S''' | |||
|- | |||
| ||[[Citrobacter sp.]]||'''S''' | |||
|- | |||
| ||[[Aeromonas sp]]||'''S''' | |||
|- | |||
| ||[[Acinetobacter sp.]]||R | |||
|- | |||
| ||[[Pseudomonas aeruginosa]]||R | |||
|- | |||
| ||[[Burkholderia cepacia]]||I | |||
|- | |||
| ||[[Stenotrophomonas maltophilia]]||R | |||
|- | |||
| ||[[Yersinia enterocolitica]]||'''S''' | |||
|- | |||
| ||[[Francisella tularensis]]||X1 | |||
|- | |||
| ||[[Brucella sp.]]||X1 | |||
|- | |||
| ||[[Legionella sp.]]||R | |||
|- | |||
| ||[[Pasteurella multocida]]||'''S''' | |||
|- | |||
| ||[[Haemophilus ducreyi]]||'''S''' | |||
|- | |||
| ||[[Vibrio vulnificus]]||X1 | |||
|- | |||
| Misc||[[Chlamydophila sp]]||X1 | |||
|- | |||
| ||[[Mycoplasm pneumoniae]]||X1 | |||
|- | |||
| ||[[Rickettsia sp]]||X1 | |||
|- | |||
| ||[[Mycobacterium avium]]||X1 | |||
|- | |||
| Anaerobes||[[Actinomyces]]||'''S''' | |||
|- | |||
| ||[[Bacteroides fragilis]]||R | |||
|- | |||
| ||[[Prevotella melaninogenica]]||I | |||
|- | |||
| ||[[Clostridium difficile]]||X1 | |||
|- | |||
| ||[[Clostridium (not difficile)]]||'''S''' | |||
|- | |||
| ||[[Fusobacterium necrophorum]]||X1 | |||
|- | |||
| ||[[Peptostreptococcus sp.]]||'''S''' | |||
|} | |||
===Key=== | |||
{{Template:Antibacterial Spectra Key}} | |||
==See Also== | ==See Also== | ||
*[[Antibiotics (Main)]] | *[[Antibiotics (Main)]] | ||
== | ==References== | ||
<references/> | |||
[[Category: | [[Category:Pharmacology]] |
Revision as of 18:21, 13 October 2017
General
- Type: 3rd generation Cephalosporin
- Dosage Forms: injectable solution, powder for injection
- Dosage Strengths: injectable solution: 1g/50mL, 2g/50mL; powder for injection: 250mg, 500mg, 1g, 2g, 10g, 100g
- Routes of Administration: IV, IM
- Common Trade Names: Rocephin
Adult Dosing
General
- 1-2g IM/IV q24h
- First ED Dose: 1g IM/IV x 1
- Max: 4g/24h
Bacterial Meningitis
- 4g IV divided q12-24h x 7-21 days
- First ED Dose: 2g IM/IV x 1
Gonococcal
- Uncomplicated, initial: 250mg IM x 1
- Also treat for chlamydia regardless of test results
- Uncomplicated, recurrent of persistent: 500-1000mg IM x 1
- Disseminated: 1g IM/IV q24h
- May switch to cefixime PO after 24-48h if clinical improvement
- Conjunctivitis: 1g IM x 1
- Prophylaxis (sexual assault victims)
- 250mg IM x 1
PID
- 250mg IM x 1
- Use with doxycycline +/- metronidazole
Sinusitis, Severe
- 1-2g IV q12-24h x 7-10 days
Endocarditis
- 1g IM/IV x 1
- 30-60 min before procedure
Proctitis, Epididymitis, Chancroid
- 250mg IM x 1
- Give with doxycycline
Surgical Prophylaxis
- 1g IV x 1
- Give 0.5-2h preop
Typhoid Fever
- 60mg/kg IV q24h x 2wk
- Max: 4g/24h
Pediatric Dosing
General (<7 Days Old)
- 50mg/kg IM/IV q24h
- First Dose: 50mg/kg IM/IV x 1
General (7 Days - 1 Month)
- <2000g
- 50mg/kg IM/IV q24h
- First Dose: 50mg/kg IM/IV x 1
- >2000g
- 50-75mg/kg IM/IV q24h
- First Dose: 50-75mg/kg IM/IV x 1
General (>1 Month - Adult)
- 50-100mg/kg IM/IV divided q12-24h
- First Dose: 50-100mg/kg IM/IV x 1
- Max: 4g/24h
Acute Otitis Media (2 Months - 12 Years)
- 50mg/kg IM/IV x 1
- Give 50mg/kg IM/IV q24h x 3 days for recurrent infection
- Max 1g/dose
Bacterial Meningitis
- 80-100mg/kg IV divided q12-24h x 7-21 days
- First Dose: 100mg/kg IV x 1
- Max: 4g/24h
Pneumonia, Community-Acquired (>3 Months)
- 50-100mg/kg/day IM/IV divided q12-24h x 10 days
- First Dose:
- Max: 2g/day
- Info: May switch to PO when possible to complete course
Special Populations
- Pregnancy Rating: B
- Lactation: Probably safe
- Renal Dosing
- Adult
- Renal failure: No initial adjustment, monitor serum levels
- Hemodialysis: give dose after dialysis, no supplement
- Peritoneal Dialysis: 750mg q12h
- Pediatric
- CrCl <10: give q24h
- Hemodialysis: 50mg/kg q24, no supplement
- Peritoneal Dialysis: 50mg/kg q24, no supplement
- Adult
- Hepatic Dosing
- Adult
- Hepatic and renal disease: max 2g/day, unless closely monitoring serum levels
- Pediatric
- May requrire dose adjustment but specific dosing not defined
- Adult
Contraindications
- Allergy to class/drug (see also Cephalosporin Cross-reactivity)
- Patients <1 month old
- Hyperbillirubinemia
- IV calcium containing product
- If a 3rd generation cephalosporin is required, consider using Cefotaxime instead
Adverse Reactions
Serious
- Anaphylaxis
- Broncospasm
- Stevens-Johnson Syndrome
- Toxic Epidermal Necrolysis
- Erythema multiforme
- Serum sickness
- Pneumonitis
- Neutropenia
- Leukopenia
- Hemolytic anemia
- Thrombocytopenia
- Hypoprothrombinemia
- Agranulocytosis
- Superinfection
- Clostridium difficile
- Colitis
- Billiary/gallbladder sludge
- Jaundice
- Pancreatitis
- Seizures
- Nephrolithiasis
- Lung/kidney calcium precipitate (neonates)
Common
- Local infection site reaction
- Eosinophilia
- Thrombocytosis
- Transaminitis
- Diarrhea
- Leukopenia
Pharmacology
- Half-life: 5.8-8.7h, 15h (CrCl 5-15)
- Metabolism: CYP450
- Excretion: Primarily urine
- Mechanism of Action: bactericidal; inhibits cell wall synthesis
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014